Gateway, 1 Macquarie Place
Level 36
Sydney, NSW 2000
Australia
61 2 8051 3043
https://www.raceoncology.com
Sector(s):
Industry:
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Daniel Tillett | Chief Executive Officer | 613.16k | N/A | N/A |
Dr. Peter M. Smith Ph.D. | Executive Director | 635 | N/A | 1963 |
Mr. Brendan Brown | Chief Financial Officer | N/A | N/A | N/A |
Prof. Tim Hammond | Interim Chief Scientific Officer | N/A | N/A | N/A |
Dr. Michelle Rashford | Chief Medical Officer | N/A | N/A | N/A |
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary | N/A | N/A | 1963 |
Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Race Oncology Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.